News

HAS Provides Conditional Reimbursement for Pirtobrutinib and Restricted Use for Upadacitinib | iPharmaCenter

ipharmaservices

5 days ago

PBS Adds Zytorvi, First Funded Immunotherapy Option for Australians with Recurrent or Metastatic Nasopharyngeal Carcinoma | iPharmaCenter

ipharmaservices

5 days ago

FDA Clears Breyanzi as the First CAR T‑Cell Therapy for Relapsed or Refractory Marginal Zone Lymphoma in the US | iPharmaCenter

Badari Andukuri

5 days ago

Johnson & Johnson Secures European Commission Approval for IMAAVY (Nipocalimab) to Treat Generalised Myasthenia Gravis

Badari Andukuri

5 days ago

Sun Pharma Launches ILUMYA in India for Psoriasis Patients | iPharmaCenter

Badari Andukuri

6 days ago

US FDA Accepts AstraZeneca’s Baxdrostat for Priority Review in Resistant Hypertension

ipharmaservices

6 days ago

FDA Approves Jaypirca for Relapsed or Refractory CLL/SLL Previously Treated with Covalent BTK Inhibitors | iPharmaCenter

ipharmaservices

6 days ago

Best‑Selling Cancer Drugs 2025: Top 10 Brands, Uses and MOA | Best selling cancer drugs | 2025 | iPharmaCenter

Badari Andukuri

7 days ago

Top 10 pharmaceutical companies by revenues | 2025 | iPharmaCenter

Badari Andukuri

Dec 3

Bristol Myers Squibb Extends Cobenfy Trial in Alzheimer’s Psychosis After DMC Recommendation | iPharmaCenter

Badari Andukuri

Dec 3

Dual Special Needs Plans (D-SNPs) and Key 2026 Changes: What Dual Eligibles Need to Know During Medicare Enrollment | iPharmaCenter

ipharmaservices

Dec 2

Eli Lilly Cuts Zepbound Prices on Single‑Dose Vials to Expand Obesity Drug Access in the US | iPharmaCenter

Badari Andukuri

Dec 2

US–Swiss Tariff Cap Impact on Pharma: How the New US–Swiss Tariff Cap Shapes Pharma and Health Security

ipharmaservices

Dec 2

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

Badari Andukuri

Dec 2

NICE increased cost effectiveness threshold from £20,000-£30,000/QALY to £25,000-£35,000/QALY

Badari Andukuri

Dec 1

CMS Launches ACCESS Outcome-Aligned Payment Model for High-Burden Chronic Conditions | iPharmaCenter

Badari Andukuri

Dec 1

FDA Clears Imfinzi as First Perioperative Immunotherapy for Resectable Gastric and GEJ Cancers | iPharmaCenter

ipharmaservices

Dec 1

EU clears Dupixent as first targeted CSU therapy in over a decade | iPharmaCenter

ipharmaservices

Nov 29

FDA Greenlights Kygevvi as Pioneering Therapy for Thymidine Kinase 2 Deficiency in Adults and Kids | iPharmaCenter

ipharmaservices

Nov 28

China NMPA Approves Pfizer’s Matazisimab (You Ruiting) for Routine Prophylaxis in Hemophilia Patients with Inhibitors | iPharmaCenter

Badari Andukuri

Nov 28